| Comparative evaluation of eight docking tools for docking and virtual screening accuracy E Kellenberger, J Rodrigo, P Muller, D Rognan Proteins: Structure, Function, and Bioinformatics 57 (2), 225-242, 2004 | 785 | 2004 |
| A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors JS Surgand, J Rodrigo, E Kellenberger, D Rognan Proteins: Structure, Function, and Bioinformatics 62 (2), 509-538, 2006 | 295 | 2006 |
| sc-PDB: a 3D-database of ligandable binding sites—10 years on J Desaphy, G Bret, D Rognan, E Kellenberger Nucleic acids research 43 (D1), D399-D404, 2015 | 258 | 2015 |
| sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank E Kellenberger, P Muller, C Schalon, G Bret, N Foata, D Rognan Journal of chemical information and modeling 46 (2), 717-727, 2006 | 223 | 2006 |
| Comparison and druggability prediction of protein–ligand binding sites from pharmacophore-annotated cavity shapes J Desaphy, K Azdimousa, E Kellenberger, D Rognan Journal of chemical information and modeling 52 (8), 2287-2299, 2012 | 160 | 2012 |
| Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5) J Garcia-Perez, P Rueda, J Alcami, D Rognan, F Arenzana-Seisdedos, ... Journal of Biological Chemistry 286 (38), 33409-33421, 2011 | 152 | 2011 |
| Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening E Kellenberger, JY Springael, M Parmentier, M Hachet-Haas, JL Galzi, ... Journal of medicinal chemistry 50 (6), 1294-1303, 2007 | 145 | 2007 |
| A simple and fuzzy method to align and compare druggable ligand‐binding sites C Schalon, JS Surgand, E Kellenberger, D Rognan Proteins: Structure, Function, and Bioinformatics 71 (4), 1755-1778, 2008 | 141 | 2008 |
| Recovering the true targets of specific ligands by virtual screening of the protein data bank N Paul, E Kellenberger, G Bret, P Müller, D Rognan Proteins: Structure, Function, and Bioinformatics 54 (4), 671-680, 2004 | 131 | 2004 |
| Small neutralizing molecules to inhibit actions of the chemokine CXCL12 M Hachet-Haas, K Balabanian, F Rohmer, F Pons, C Franchet, S Lecat, ... Journal of Biological Chemistry 283 (34), 23189-23199, 2008 | 128 | 2008 |
| Dual function for U2AF35 in AG-dependent pre-mRNA splicing S Guth, E Kellenberger, J Valcárcel Molecular and cellular biology, 2001 | 128 | 2001 |
| sc-PDB: a database for identifying variations and multiplicity of ‘druggable’binding sites in proteins J Meslamani, D Rognan, E Kellenberger Bioinformatics 27 (9), 1324-1326, 2011 | 122 | 2011 |
| Flavonoids as inhibitors of human CD38 E Kellenberger, I Kuhn, F Schuber, H Muller-Steffner Bioorganic & medicinal chemistry letters 21 (13), 3939-3942, 2011 | 114 | 2011 |
| New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection J Garcia-Perez, P Rueda, I Staropoli, E Kellenberger, J Alcami, ... Journal of Biological Chemistry 286 (7), 4978-4990, 2011 | 105 | 2011 |
| How to measure the similarity between protein ligand-binding sites? E Kellenberger, C Schalon, D Rognan Current Computer-Aided Drug Design 4 (3), 209, 2008 | 97 | 2008 |
| Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs E Kellenberger, A Hofmann, RJ Quinn Natural product reports 28 (9), 1483-1492, 2011 | 95 | 2011 |
| Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems E Kellenberger, N Foata, D Rognan Journal of chemical information and modeling 48 (5), 1014-1025, 2008 | 80 | 2008 |
| A bright future for fragment-based drug discovery: what does it hold? C Jacquemard, E Kellenberger Expert opinion on drug discovery 14 (5), 413-416, 2019 | 74 | 2019 |
| Structural insights into the molecular basis of the ligand promiscuity N Sturm, J Desaphy, RJ Quinn, D Rognan, E Kellenberger Journal of chemical information and modeling 52 (9), 2410-2421, 2012 | 71 | 2012 |
| Selective Fluorescent Nonpeptidic Antagonists For Vasopressin V2 GPCR: Application To Ligand Screening and Oligomerization Assays. S Loison, M Cottet, H Orcel, H Adihou, R Rahmeh, L Lamarque, ... Journal of medicinal chemistry 55 (20), 8588-8602, 2012 | 65 | 2012 |
